Hualan Biological Engineering Beheer

Beheer criteriumcontroles 4/4

De CEO Hualan Biological Engineering is Bei Fan, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. bezit rechtstreeks 0.15% van de aandelen van het bedrijf, ter waarde CN¥ 44.08M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 5.1 jaar.

Belangrijke informatie

Bei Fan

Algemeen directeur

CN¥1.1m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.6yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Nov 18

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate

Oct 07

Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Aug 22

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 26

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Jun 09

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Jun 07

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

May 21

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Feb 27

CEO

Bei Fan (52 yo)

2.6yrs

Tenure

CN¥1,100,000

Compensatie

Ms. Bei Fan serves as a General Manager of Hualan Biological Engineering Inc since April 28, 2022. Ms. Fan served as Managing Deputy General Manager of Hualan Biological Engineering Inc. She served as Secr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bei Fan	GM & Director	2.6yrs	CN¥1.10m	0.15% CN¥ 44.1m
Jun Min Xie	CFO & Secretary of the Board of Directors	11.6yrs	CN¥640.00k	0.075% CN¥ 22.6m
Bao Xian Zhang	Deputy GM & Director	no data	CN¥910.00k	0.078% CN¥ 23.4m
Xiao Wei Ma	Deputy General Manager	2.6yrs	CN¥910.00k	0.089% CN¥ 26.8m
Jun Liu	Deputy General Manager	2.6yrs	CN¥410.00k	0.015% CN¥ 4.7m
Zhengyue Chen	Deputy General Manager	3.7yrs	CN¥550.00k	0.0044% CN¥ 1.3m

2.6yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002007 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bei Fan	GM & Director	17.6yrs	CN¥1.10m	0.15% CN¥ 44.1m
Bao Xian Zhang	Deputy GM & Director	16.7yrs	CN¥910.00k	0.078% CN¥ 23.4m
Yunlong Wang	Independent Director	4.6yrs	CN¥100.00k	geen gegevens
Kang An	Chairman of the Board of Directors	24.2yrs	CN¥1.40m	17.92% CN¥ 5.4b
Ruo Wen Pan	Director	2.6yrs	geen gegevens	0.10% CN¥ 31.3m
Zhi Guo Su	Independent Director	2.6yrs	CN¥100.00k	geen gegevens
Wanli Liu	Independent Director	4.6yrs	CN¥100.00k	geen gegevens
Wenqi An	Director	2.6yrs	geen gegevens	0.020% CN¥ 6.1m
Chao Yuan Ma	Supervisor	7.6yrs	geen gegevens	geen gegevens
Lin Lin Cai	Supervisor	7.6yrs	geen gegevens	geen gegevens
Yanchao Wang	Supervisor	5.6yrs	geen gegevens	geen gegevens
Wenjue An	Director	2.6yrs	geen gegevens	0.0022% CN¥ 660.0k

5.1yrs

Gemiddelde duur

48.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002007 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Hualan Biological Engineering Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Less than half of directors are independent

Hualan Biological Engineering Inc., Annual General Meeting, Apr 28, 2022

Recent updates

Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate

Hualan Biological Engineering Inc. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 16%

Price target decreased by 7.4% to CN¥22.68

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Hualan Biological Engineering Inc. to Report First Half, 2024 Results on Aug 30, 2024

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Dividend of CN¥0.30 announced

Hualan Biological Engineering Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Hualan Biological Engineering Inc. to Report Q1, 2024 Results on Apr 26, 2024

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Hualan Biological Engineering Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥26.17

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2021)

Investor sentiment improved over the past week

Hualan Biological Engineering Inc. Announces Final Cash Dividend on A Shares for 2021, Payable on 16 June 2022

Price target decreased to CN¥27.73

Less than half of directors are independent

Investor sentiment improved over the past week

Consensus revenue estimates increase by 11%

Price target decreased to CN¥33.57

Price target decreased to CN¥33.57

Hualan Biological Engineering Inc., Annual General Meeting, Apr 28, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Hualan Biological Engineering Inc. Proposes Final Dividend for the Year 2021

Consensus revenue estimates fall by 32%

Price target decreased to CN¥36.80

Third quarter 2021 earnings released: EPS CN¥0.33 (vs CN¥0.25 in 3Q 2020)

Price target decreased to CN¥41.06

Investor sentiment deteriorated over the past week

Price target decreased to CN¥46.66

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.89 (vs CN¥0.71 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.88 (vs CN¥0.70 in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day low: CN¥39.55

Hualan Biological Engineering Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment improved over the past week

New 90-day high: CN¥53.98

Investor sentiment improved over the past week

New 90-day low: CN¥42.50

New 90-day low: CN¥46.08

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations, earnings disappoint

Market pulls back on stock over the past week

Earnings released

New 90-day high - CN¥59.83

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd